$ACUR
ACURA PHARMACEUTICALS, INC

2014 Q2 Form 10-Q Financial Statement

#000114420414046751 Filed on August 04, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2013 Q4 2013 Q2
Revenue $35.00K $35.00K $1.000K
YoY Change 3400.0%
Cost Of Revenue $40.00K $40.00K $0.00
YoY Change
Gross Profit -$10.00K $0.00 $0.00
YoY Change
Gross Profit Margin -28.57% 0.0% 0.0%
Selling, General & Admin $1.916M $2.790M $1.975M
YoY Change -2.99% 50.81% 55.51%
% of Gross Profit
Research & Development $1.281M $800.0K $805.0K
YoY Change 59.13% -33.88% -12.4%
% of Gross Profit
Depreciation & Amortization $30.00K $30.00K $40.00K
YoY Change -25.0% 0.0% 33.33%
% of Gross Profit
Operating Expenses $3.307M $3.516M $3.141M
YoY Change 5.28% 15.01% 43.49%
Operating Profit -$3.272M -$3.481M -$3.140M
YoY Change 4.2% 13.87% 43.44%
Interest Expense $302.0K $60.00K $0.00
YoY Change -25.0% -100.0%
% of Operating Profit
Other Income/Expense, Net -$249.0K $64.00K
YoY Change -489.06% 540.0%
Pretax Income -$3.521M -$3.420M -$3.076M
YoY Change 14.47% 13.25% 41.17%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.521M -$3.417M -$3.076M
YoY Change 14.47% 13.3% 41.17%
Net Earnings / Revenue -10060.0% -9762.86% -307600.0%
Basic Earnings Per Share -$0.35 -$0.07 -$0.07
Diluted Earnings Per Share -$0.35 -$0.07 -$0.07
COMMON SHARES
Basic Shares Outstanding 48.85M shares 48.32M shares 47.23M shares
Diluted Shares Outstanding 48.85M shares 47.23M shares

Balance Sheet

Concept 2014 Q2 2013 Q4 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.36M $26.07M $19.47M
YoY Change -10.82% -4.92% -37.52%
Cash & Equivalents $3.541M $12.34M $584.0K
Short-Term Investments $13.82M $13.73M $18.88M
Other Short-Term Assets $740.0K $820.0K $530.0K
YoY Change 39.62% 203.7% 23.26%
Inventory $445.0K $251.0K $400.0K
Prepaid Expenses
Receivables $90.00K $190.0K $10.00K
Other Receivables $100.0K $120.0K $130.0K
Total Short-Term Assets $18.73M $27.45M $20.49M
YoY Change -8.58% -1.92% -35.46%
LONG-TERM ASSETS
Property, Plant & Equipment $928.0K $941.0K $1.006M
YoY Change -7.75% -10.55% -7.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $240.0K $10.00K
YoY Change 1900.0% 2300.0%
Total Long-Term Assets $3.127M $1.177M $1.014M
YoY Change 208.38% 10.21% -6.97%
TOTAL ASSETS
Total Short-Term Assets $18.73M $27.45M $20.49M
Total Long-Term Assets $3.127M $1.177M $1.014M
Total Assets $21.86M $28.63M $21.51M
YoY Change 1.65% -1.48% -34.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $114.0K $274.0K $328.0K
YoY Change -65.24% -72.43% 368.57%
Accrued Expenses $1.444M $541.0K $675.0K
YoY Change 113.93% 30.99% -17.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $477.0K $0.00
YoY Change
Total Short-Term Liabilities $2.379M $1.107M $1.076M
YoY Change 121.1% -22.26% 20.9%
LONG-TERM LIABILITIES
Long-Term Debt $9.180M $9.600M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $10.00K
YoY Change -100.0%
Total Long-Term Liabilities $9.180M $9.600M $10.00K
YoY Change 91700.0% 95900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.379M $1.107M $1.076M
Total Long-Term Liabilities $9.180M $9.600M $10.00K
Total Liabilities $11.56M $10.71M $1.081M
YoY Change 969.47% 649.27% 21.46%
SHAREHOLDERS EQUITY
Retained Earnings -$356.7M -$349.1M -$342.5M
YoY Change 4.15% 4.15%
Common Stock $367.0M $367.0M $363.0M
YoY Change 1.08% 1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.30M $17.92M $20.42M
YoY Change
Total Liabilities & Shareholders Equity $21.86M $28.63M $21.51M
YoY Change 1.65% -1.48% -34.52%

Cashflow Statement

Concept 2014 Q2 2013 Q4 2013 Q2
OPERATING ACTIVITIES
Net Income -$3.521M -$3.417M -$3.076M
YoY Change 14.47% 13.3% 41.17%
Depreciation, Depletion And Amortization $30.00K $30.00K $40.00K
YoY Change -25.0% 0.0% 33.33%
Cash From Operating Activities -$3.070M -$3.160M -$4.080M
YoY Change -24.75% 71.74% 104.0%
INVESTING ACTIVITIES
Capital Expenditures -$2.020M $0.00 -$20.00K
YoY Change 10000.0% -100.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$240.0K $3.180M $970.0K
YoY Change -124.74% -115.91%
Cash From Investing Activities -$2.260M $3.180M $950.0K
YoY Change -337.89% -115.9% -2475.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 9.770M 250.0K
YoY Change -100.0% -2600.0%
NET CHANGE
Cash From Operating Activities -3.070M -3.160M -4.080M
Cash From Investing Activities -2.260M 3.180M 950.0K
Cash From Financing Activities 0.000 9.770M 250.0K
Net Change In Cash -5.330M 9.790M -2.880M
YoY Change 85.07% -144.83% 40.49%
FREE CASH FLOW
Cash From Operating Activities -$3.070M -$3.160M -$4.080M
Capital Expenditures -$2.020M $0.00 -$20.00K
Free Cash Flow -$1.050M -$3.160M -$4.060M
YoY Change -74.14% 73.63% 107.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2013Q2 us-gaap Revenues
Revenues
1000 USD
CY2014Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1758000 USD
CY2014Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2522000 USD
CY2014Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2741000 USD
CY2014Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
2979000 USD
CY2014Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
0 USD
CY2014Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 USD
CY2013Q4 us-gaap Secured Debt
SecuredDebt
10000000 USD
CY2014Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2200000 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.15
us-gaap Royalty Revenue
RoyaltyRevenue
5000 USD
CY2013Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1000 USD
CY2014Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
34000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
73000 USD
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
us-gaap Revenues
Revenues
5000 USD
us-gaap Revenues
Revenues
77000 USD
CY2014Q2 us-gaap Revenues
Revenues
35000 USD
acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
0 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4175000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1975000 USD
CY2014Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1916000 USD
CY2014Q2 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
42000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7389000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7175000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7384000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
81000 USD
us-gaap Inventory Write Down
InventoryWriteDown
361000 USD
us-gaap Inventory Write Down
InventoryWriteDown
201000 USD
CY2013Q2 us-gaap Inventory Write Down
InventoryWriteDown
361000 USD
CY2014Q2 us-gaap Inventory Write Down
InventoryWriteDown
68000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2831000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2719000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
805000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1281000 USD
acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
80000 USD
CY2013Q2 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
0 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4197000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3076000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3521000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-79000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
50000 USD
CY2013Q2 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-131000 USD
CY2014Q2 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
21000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-79000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
50000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3076000 USD
CY2013Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-131000 USD
CY2014Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
21000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3521000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7373000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7559000 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3207000 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3500000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
97000 USD
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
71000 USD
CY2014Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
90000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-511000 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
64000 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-249000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7294000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7609000 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47215000 shares
CY2014Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
53000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48846000 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47228000 shares
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
9000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-5000 USD
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48848000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47215000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48846000 shares
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47228000 shares
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48848000 shares
CY2013Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
830000 shares
CY2013Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-7000 USD
CY2014Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
830000 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-7294000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7609000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
61000 USD
acur Shares Withheld For Tax Value
SharesWithheldForTaxValue
525000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7398000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6053000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7612000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1540000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8604000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1361000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
969000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2226000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
716000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
529000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-463000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-520000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6892000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8799000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7476000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
348000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
43000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 USD
CY2014Q2 acur Restricted Stock Units Sale Price
RestrictedStockUnitsSalePrice
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000 USD
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
46800000 USD
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
137600000 USD
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2800000 USD
acur Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
46386 shares
acur Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
48846 shares
CY2013Q2 acur Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
46399 shares
CY2014Q2 acur Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
48848 shares
us-gaap Depreciation And Amortization
DepreciationAndAmortization
69000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
58000 USD
acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
390000 USD
acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
201000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
630000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
455000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
93000 USD
acur Amortization Of Bond Premium In Marketable Securities
AmortizationOfBondPremiumInMarketableSecurities
0 USD
acur Amortization Of Bond Premium In Marketable Securities
AmortizationOfBondPremiumInMarketableSecurities
138000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-108000 USD
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
829 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
829 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47215 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48846 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47228 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48848 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5198 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5934 shares
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
91000 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-18000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
532000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
394000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-43000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 USD
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5198 shares
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5934 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
455000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
207000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-83000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
49000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
7000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-666000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-160000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
262000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
902000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3100000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6100000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6800000 USD
CY2014Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
13800000 USD
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
13700000 USD
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13700000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13700000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
100000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
300000 USD
CY2014Q2 acur Increase In Inventory Reserves
IncreaseInInventoryReserves
450000 USD
CY2014Q2 us-gaap Inventory Adjustments
InventoryAdjustments
200000 USD
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
219000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
78000 USD
CY2014Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
214000 USD
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
293000 USD
CY2014Q2 us-gaap Interest Payable Current
InterestPayableCurrent
162000 USD
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2014Q2 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
8000 USD
CY2013Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
1000 USD
CY2014Q2 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
15000 USD
CY2013Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
15000 USD
CY2014Q2 acur Manufacturing Services Costs
ManufacturingServicesCosts
0 USD
CY2013Q4 acur Manufacturing Services Costs
ManufacturingServicesCosts
14000 USD
CY2014Q2 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
175000 USD
CY2013Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
0 USD
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
651000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
140000 USD
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000000 USD
CY2014Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0835 pure
CY2014Q2 acur Debt Default Long Term Debt Percentage
DebtDefaultLongTermDebtPercentage
0.1335 pure
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-12-01
acur Debt Instrument Deferment Of Amortization Date Description
DebtInstrumentDefermentOfAmortizationDateDescription
The Amortization Date is April 1, 2015, but shall automatically become April 1, 2016 if we achieve 75% of our projected Nexafed cash receipts and 75% of our projected Aversion Oxycodone cash receipts for the fiscal year ending December 31, 2014 (collectively, the First Revenue Event).
acur Debt Instrument Further Deferment Of Amortization Date Description
DebtInstrumentFurtherDefermentOfAmortizationDateDescription
The Amortization Date will be further deferred until April 1, 2017 if the First Revenue Event occurs and in addition we achieve 75% of our projected Nexafed cash receipts and 75% of our projected Aversion Oxycodone cash receipts for the fiscal year ending December 31, 2015 (collectively, the Second Revenue Event).
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2379000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3541000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12340000 USD
CY2014Q2 us-gaap Marketable Securities
MarketableSecurities
13820000 USD
CY2013Q4 us-gaap Marketable Securities
MarketableSecurities
13733000 USD
CY2014Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
86000 USD
CY2014Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
50000 USD
acur Debt Consulting Placement Fee
DebtConsultingPlacementFee
100000 USD
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
231000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0 USD
CY2013Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
120000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1107000 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21860000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
10299000 USD
CY2014Q2 us-gaap Liabilities
Liabilities
11561000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
32000 USD
CY2013 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
19000 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
928000 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
18733000 USD
CY2013Q4 us-gaap Other Assets
OtherAssets
5000 USD
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
114000 USD
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1444000 USD
CY2014Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
37000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
629000 USD
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
366463000 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356721000 USD
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
69000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
10707000 USD
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
488000 USD
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
9600000 USD
us-gaap Product Warranty Accrual Additions From Business Acquisition
ProductWarrantyAccrualAdditionsFromBusinessAcquisition
0 USD
CY2013Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
194000 USD
CY2014Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
102000 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
546000 USD
CY2014Q2 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
193000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
186000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
27453000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
941000 USD
CY2014Q2 us-gaap Other Assets
OtherAssets
3000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0186 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.14 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Product Warranty Accrual Additions From Business Acquisition
ProductWarrantyAccrualAdditionsFromBusinessAcquisition
2000000 USD
acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
-251000 USD
CY2014Q2 us-gaap Assets
Assets
21860000 USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
274000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
541000 USD
CY2014Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
445000 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
251000 USD
CY2014Q2 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
196000 USD
CY2013Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
231000 USD
CY2013Q4 us-gaap Assets
Assets
28630000 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5000 USD
CY2014Q2 us-gaap Deferred Revenue
DeferredRevenue
307000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
287000 USD
CY2014Q2 us-gaap Long Term Debt
LongTermDebt
9182000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
483000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
366533000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349112000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
17923000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28630000 USD
acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
0 USD
acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
8000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
3141000 USD
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
3307000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7098000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3140000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3272000 USD
acur Percentage Of Royalty
PercentageOfRoyalty
0.05 pure
acur Payment For Termination
PaymentForTermination
2000000 USD
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
300000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
4000 USD
CY2014Q2 acur Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
100000 USD
CY2013Q4 acur Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
0 USD
CY2014Q2 acur Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
0 USD
CY2013Q4 acur Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
360000 USD
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48848000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48325000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48848000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48325000 shares
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
22000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
28000 USD
CY2014Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
341000 USD
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
400000 USD
CY2014Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3300000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
510000 USD
CY2013Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2014Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
255000 USD
acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
0 USD
acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
59000 USD
CY2013Q2 acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
0 USD
CY2014Q2 acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
30000 USD
us-gaap Debt Issuance Costs
DebtIssuanceCosts
0 USD
us-gaap Debt Issuance Costs
DebtIssuanceCosts
34000 USD
CY2013Q2 us-gaap Debt Issuance Costs
DebtIssuanceCosts
0 USD
CY2014Q2 us-gaap Debt Issuance Costs
DebtIssuanceCosts
17000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
603000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2014Q2 us-gaap Interest Expense
InterestExpense
302000 USD
acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
0 USD
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
ACURA PHARMACEUTICALS, INC
dei Entity Central Index Key
EntityCentralIndexKey
0000786947
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Trading Symbol
TradingSymbol
ACUR
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48847982 shares
CY2014Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
477000 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2014Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
260000 USD
CY2013Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0 USD
CY2014Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
185000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
501000 USD
CY2014Q2 us-gaap Other Inventory
OtherInventory
445000 USD
CY2013Q4 us-gaap Other Inventory
OtherInventory
501000 USD
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
250000 USD
CY2014Q2 us-gaap Inventory Net
InventoryNet
445000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
251000 USD
acur Share Based Compensation Expense Recognized In Operations
ShareBasedCompensationExpenseRecognizedInOperations
630000 USD
acur Share Based Compensation Expense Recognized In Operations
ShareBasedCompensationExpenseRecognizedInOperations
487000 USD
CY2013Q2 acur Share Based Compensation Expense Recognized In Operations
ShareBasedCompensationExpenseRecognizedInOperations
315000 USD
CY2014Q2 acur Share Based Compensation Expense Recognized In Operations
ShareBasedCompensationExpenseRecognizedInOperations
289000 USD

Files In Submission

Name View Source Status
0001144204-14-046751-index-headers.html Edgar Link pending
0001144204-14-046751-index.html Edgar Link pending
0001144204-14-046751.txt Edgar Link pending
0001144204-14-046751-xbrl.zip Edgar Link pending
acur-20140630.xml Edgar Link completed
acur-20140630.xsd Edgar Link pending
acur-20140630_cal.xml Edgar Link unprocessable
acur-20140630_def.xml Edgar Link unprocessable
acur-20140630_lab.xml Edgar Link unprocessable
acur-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlogo.jpg Edgar Link pending
v382413_10q.htm Edgar Link pending
v382413_ex10-1.htm Edgar Link pending
v382413_ex31-1.htm Edgar Link pending
v382413_ex31-2.htm Edgar Link pending
v382413_ex32-1.htm Edgar Link pending